Kevin Chu, MD
Urology · Los Angeles, CANPI 1790147247
Payments from drug & device makers
Across 205 payments — averaging $81.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endo Pharmaceuticals Inc.$6K
- Boston Scientific$4K
- Coloplast$3K
- Astellas Pharma US Inc$478
- AbbVie$436
- Pfizer$278
- plus $2K from 21 others
What the payments were for
- Consulting fees$3,78023%
- Travel & lodging$4,36726%
- Food & beverage$8,22549%
- Education$4243%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endo Pharmaceuticals Inc. | 21 | $6,438 |
| Boston Scientific | 57 | $4,163 |
| Coloplast | 24 | $2,935 |
| Astellas Pharma US Inc | 11 | $478 |
| AbbVie | 22 | $436 |
| Pfizer | 14 | $278 |
| Endo USA, Inc. | 2 | $278 |
| Myriad Genetic Laboratories, Inc. | 5 | $265 |
| Aytu Biopharma, Inc. | 1 | $186 |
| Sumitomo Pharma America, Inc. | 7 | $170 |
| Johnson & Johnson | 8 | $160 |
| Bayer | 6 | $157 |
| Acerus Pharmaceuticals Corporation | 2 | $155 |
| Merck | 4 | $106 |
| Urogen Pharma, Inc. | 2 | $83 |
| 180 Medical, Inc. | 2 | $81 |
| Tolmar, Inc. | 3 | $77 |
| Hollister Incorporated | 2 | $52 |
| Antares Pharma, Inc. | 1 | $50 |
| Novartis | 2 | $46 |
| Myovant Sciences Inc. | 2 | $45 |
| Progenics Pharmaceuticals, Inc. | 2 | $44 |
| Blue Earth Diagnostics | 1 | $26 |
| Procept Biorobotics Corporation | 1 | $26 |
| Urovant Sciences Inc | 1 | $24 |
| Agiliti Surgical, Inc. | 1 | $24 |
| Sagent Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIAFLEX$6,247
- TITAN$2,417
- AdVance XP$1,362
- Natesto$310
- GENERAL ERECTILE DYSFUNCTION$281
- AMS 700 CXR RTE KIT$274
- GREENLIGHT$248
- REZUM$196
- GENERAL KIDNEY STONE DISEASE$123
- TACTRA$112
- XTANDI$108
How this compares
$16,797 in reported general payments places this provider in the 80th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 33 | $35,207 |
| GemtesaVibegron | 30 | $34,597 |
| Trospium Chloride ErTrospium Chloride | 27 | $10,957 |
| Tamsulosin Hcl | 462 | $5,478 |
| Estradiol | 44 | $2,842 |
| Tolterodine Tartrate ErTolterodine Tartrate | 18 | $2,705 |
| Oxybutynin Chloride ErOxybutynin Chloride | 108 | $2,535 |
| Finasteride | 180 | $2,472 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 49 | $1,292 |
| Methenamine Hippurate | 20 | $1,270 |
| Dutasteride | 28 | $713 |
| Ciprofloxacin Hcl | 69 | $287 |
| Testosterone Cypionate | 12 | $285 |
| Sildenafil Citrate | 40 | $220 |
| Doxycycline Hyclate | 11 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $478 | $35,20733 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $170 | $34,59730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,324 urology providers in California.
Other urology in Los Angeles
- Karim ChamieLos Angeles$4.3M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- John KowalczykLos Angeles$1.8M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.7M
- Brian ShuchLos Angeles$1.5M
- David JosephsonLos Angeles$1.5M
- Saum GhodoussipourLos Angeles$1.1M
- Stuart HoldenLos Angeles$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.